Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAS1R3 | Q7RTX0 | 2/20 | 0.53 |
| ▸ | TAS1R1 | Q7RTX1 | 2/20 | 0.53 |
| ▸ | TAS1R2 | Q8TE23 | 2/20 | 0.53 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.49 |
| ▸ | NPC1 | O15118 | 4/20 | 0.48 |
| ▸ | RAB9A | P51151 | 4/20 | 0.48 |
| ▸ | MCHR1 | Q99705 | 4/20 | 0.47 |
| ▸ | DPP4 | P27487 | 3/20 | 0.46 |
| ▸ | KCNH2 | Q12809 | 3/20 | 0.46 |
| ▸ | DPP7 | Q9UHL4 | 3/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.45 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.44 |
| ▸ | SMYD3 | Q9H7B4 | 3/20 | 0.44 |
| ▸ | HPGD | P15428 | 2/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17818390 | 0.82 | MAPK14 (0.53) | MAPK14NPC1RAB9AKMT2ASMN1; SMN2 | |
| SCHEMBL16236296 | 0.81 | NPC1 (0.50) | MAPK14NPC1RAB9AKMT2AMEN1 | |
| SCHEMBL531986 | 0.81 | MCHR1 (0.64) | TAS1R3TAS1R1TAS1R2MAPK14NPC1 | |
| SCHEMBL2868187 | 0.78 | TAS1R3 (0.58) | TAS1R3TAS1R1TAS1R2MAPK14NPC1 | |
| SCHEMBL31591018 | 0.77 | LMNA (0.44) | RAB9AKMT2AMEN1SMN1; SMN2L3MBTL1 | |
| SCHEMBL13790808 | 0.77 | TAS1R3 (0.60) | TAS1R3TAS1R1TAS1R2MAPK14NPC1 | |
| SCHEMBL531505 | 0.77 | TAS1R3 (0.64) | TAS1R3TAS1R1TAS1R2MAPK14NPC1 | |
| SCHEMBL2060027 | 0.77 | TAS1R3 (0.57) | TAS1R3TAS1R1TAS1R2MAPK14NPC1 | |
| SCHEMBL2864006 | 0.77 | TAS1R3 (0.57) | TAS1R3TAS1R1TAS1R2MAPK14NPC1 | |
| SCHEMBL24359908 | 0.75 | MCHR1 (0.60) | TAS1R3TAS1R1TAS1R2MAPK14NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2997030-B1 | PYRROLO[2,3-D]PYRIMIDINE DERIVATIVES, PROCESS FOR THEIR PREPARATION AND THEIR USE AS KINASE INHIBITORS | NERVIANO MEDICAL SCIENCES SRL (IT) | 2017-08-09 | — | — | EP | disclosed |
| US-9682083-B2 | Pyrrolo[2,3-D]pyrimidine derivatives, process for their preparation and their use as kinase inhibitors | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2017-06-20 | — | — | US | disclosed |
| US-20160166575-A1 | PYRROLO[2,3-D]PYRIMIDINE DERIVATIVES, PROCESS FOR THEIR PREPARATION AND THEIR USE AS KINASE INHIBITORS | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2016-06-16 | — | — | US | disclosed |
| CN-105431436-A | Pyrrolo [2,3-D ] pyrimidine derivatives, processes for their preparation and their use as kinase inhibitors | NERVIANO MEDICAL SCIENCES SRL | 2016-03-23 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160166575-A1 | PYRROLO[2,3-D]PYRIMIDINE DERIVATIVES, PROCESS FOR THEIR PREPARATION AND THEIR USE AS KINASE INHIBITORS | RET, DCK, PRKD2 | TAS1R3 3810/4885TAS1R1 3865/4885TAS1R2 3885/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.